A recent study in ACS Pharmacology & Translational Science discovered that a temporary spike in stress hormones, specifically corticosterone, plays...
Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’) a pharmaceutical company developing cannabinoid pharmaceutical...
Awakn Life Sciences has submitted a Clinical Trial Application for a phase III trial for its lead program for the treatment of Severe Alcohol Use Disorder....
Investing in biotech stocks is not for the meek. Losses can be very large and occur very quickly. In fact, I’ve uncovered seven of the top...
AWAKN-P001 Is a N-methyl-D-aspartate Receptor-Modulating Drug Used in Combination with Psycho-Social Support for The Treatment of Severe Alcohol Use Disorder...
Will PharmaTher be the next company to get a psychedelic medicine to market? The post PharmaTher Submits New Drug Application to the FDA appeared first...
The newly granted U.S. patent covers deuterated 5-methoxy-dimethyltryptamine (5-MeO-DMT) analogs. The post Cybin Granted U.S. Patent for 5-MeO-DMT appeared...
Results of the Usona Institute’s Phase 2 trial using psilocybin for depression were published yesterday. The post Usona Publishes Results of Phase 2...
Reset Pharma has licensed Filament’s botanical psilocybin drug candidate for a phase 2 clinical trial studying demoralization syndrome Filament Health...
COMPASS Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced...